CDK4 and breast cancer: Detailed mechanisms of resistance to CDK4/6i in breast cancer have been the subject of several recent reviews (11–15), but as a brief summary, current evidence largely points towards a unifying theme of eliminating hypophosphorylated pRb to allow progression through the G1 cell cycle checkpoint.